TheracosBio teams with Mark Cuban's Cost Plus to launch Brenzavvy at bargain price

For its recently approved SGLT2 Brenzavvy (bexagliflozin), TheracosBio has a simple and powerful answer—with a price that undercuts the competition by roughly 1,000%.

Working through Mark Cuban’s online distributor Cost Plus Drug Company, TheracosBio will charge $47.85 plus shipping and handling for a 30-day supply of Brenzavvy. The price is a stunning departure from the going rate for a monthlong regimen of Boehringer Ingelheim and Eli Lilly’s Jardiance ($578) or AstraZeneca’s Farxiga ($551).